24 / 31
Beneficio de IO tras QT-RT secuencial
•
PACIFIC 5 Phase 3 trial: NTC03706690
• Unresectable, Stage IIIA-B
NSCLC without
progression after definitive
platinum-based
CONCURRENT or
SEQUENTIAL CRT
• 18 years or older
• WHO PS score 0 or 1
• PD-L1 known
DURVALUMAB 1500 mg
c/4s until PD
Placebo c/4s until PD
Key secondary
endpoint
• OS
Primary endpoint
• PFS
R
Dudas en CPNM estadio
III irresecable